RecruitingPhase 2Phase 3NCT05878951

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms


Sponsor

Northwestern University

Enrollment

80 participants

Start Date

Jul 13, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 89 Years

Inclusion Criteria4

  • Males 18 -89 undergoing HoLEP
  • Component of OAB symptoms including frequency, nocturia, urgency, and/or urge related incontinence
  • Willing to sign the Informed Consent Form
  • Able to read, understand, and complete patient questionnaires.

Exclusion Criteria6

  • Allergy or hypersensitivity to OnabotulinumtoxinA injections
  • Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP
  • Anticipated need for perineal urethrostomy at the time of HoLEP
  • Prior pelvic radiation or patients with a history of bladder cancer with or without BCG therapy
  • Patients who lack decisional capacity
  • Active urinary tract infection

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOnabotulinumtoxinA

Intra-detrusor OnabotulinumtoxinA is commonly known as botox


Locations(1)

Northwestern Medicine

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05878951


Related Trials